Quantcast

Latest Prasugrel Stories

2012-08-29 07:53:39

The findings were presented by Dr Jolanta Siller-Matula from Medical University of Vienna Standard antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) consists of a dual antiplatelet therapy with aspirin and an ADP receptor inhibitor such as clopidogrel. But measurements of platelet aggregation in clopidogrel treated patients indicate that one patient in four is a non-responder to the drug. Such non-responsiveness is attributed to clopidogrel's...

2012-08-27 19:48:03

Prasugrel versus clopidogrel for ACS patients managed without revascularization The first trial to study the effect of platelet inhibition in patients with acute coronary syndromes managed medically without revascularization has found no significant difference between prasugrel and clopidogrel in the prevention of death, myocardial infarction or stroke. The findings, from the phase III Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary...

2012-08-27 11:48:32

Potential long-term benefit observed for first time in ACS patients The first trial to study patients with acute coronary syndrome who do not undergo coronary stenting or bypass surgery found no significant difference between two anti-clotting drugs — prasugrel and clopidogrel — in preventing the first occurrence of death, heart attack or stroke, according to Duke University Medical Center cardiologists. The study also showed no difference in serious bleeding complications....

2012-03-26 23:35:35

Researchers report no significant difference in high versus low dose aspirin in preventing recurring cardiovascular events. Each year, more than one million Americans suffer a heart attack and nearly all patients are prescribed a daily aspirin and an antiplatelet medication during recovery.  However, the optimal aspirin dose has been unclear.  Now, new research from Brigham and Women's Hospital (BWH) reports that there is no significant difference between high versus low dose...

2012-03-26 23:31:44

New research finds ongoing treatment with ticagrelor safe and effective in patients with acute coronary syndrome. Ticagrelor, a potent anti-platelet medication, was approved by the Food and Drug Administration in the summer of 2011 and is known to significantly reduce the risk of stroke, heart attack, vascular death and death overall in patients with acute coronary syndromes (ACS), which are characterized by symptoms related to obstruction in coronary arteries, which supply blood to the...

2012-03-26 10:03:33

Percutaneous coronary intervention (PCI), also known as coronary angioplasty or angioplasty, is a procedure used to treat acute coronary syndromes. PCI involves opening a blocked blood vessel by threading and inflating a balloon-tipped tube into the vessel. Sometimes a stent is also inserted to keep the blood vessel open. While undergoing PCI treatment, doctors usually give patients medicine to prevent complications that may occur from the procedure. In a new study by researchers at...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'